Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 11/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.62 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769630 | 0.96 | MAPK13 (0.64) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5772078 | 0.93 | MAPK13 (0.67) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5769123 | 0.93 | MAPK14 (0.64) | MAPK13MAPK12MAPK11MAPK14BRAF | |
| SCHEMBL5769695 | 0.93 | MAPK13 (0.69) | MAPK13MAPK12MAPK11MAPK14BRAF | |
| SCHEMBL5771421 | 0.92 | MAPK13 (0.64) | MAPK13MAPK12MAPK11MAPK14BRAF | |
| SCHEMBL5770568 | 0.92 | MAPK13 (0.65) | MAPK13MAPK12MAPK11MAPK14BRAF | |
| SCHEMBL5772039 | 0.91 | MAPK13 (0.63) | MAPK13MAPK12MAPK11MAPK14BRAF | |
| SCHEMBL5770941 | 0.91 | MAPK13 (0.67) | MAPK13MAPK12MAPK11MAPK14BRAF | |
| SCHEMBL5770957 | 0.91 | MAPK14 (0.64) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5769482 | 0.91 | MAPK13 (0.74) | MAPK13MAPK12MAPK11MAPK14BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0988301-B1 | IMIDAZOLYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-6989395-B2 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2006-01-24 | — | — | US | disclosed |
| US-20040038991-A1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
| US-6602877-B1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2003-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038991-A1 | Imidazolyl-cyclic acetals | CBR1, LBR, CBR3 | MAPK13 1610/4885MAPK12 2766/4885MAPK11 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.